We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The characteristics, diagnosis, epidemiology of hantaviruses.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Employment Appeal Tribunal Judgment of Mrs Justice Eady on 3 May 2024.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Get help and extra support when dealing with HMRC if you have additional needs - for example you have a disability or health condition, if English is not your first language or if you’re experiencing domestic abuse or financial hardship.
Patient experience statistics: England
Find out about the long-term effects some people can have after having COVID-19.
Information for clinicians on the characteristics, diagnosis and epidemiology of infections caused by Chlamydia psittaci.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Advice for health professionals on tick-borne encephalitis (TBE) including symptoms, diagnosis and epidemiology.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Advice to help lower the chance of passing mpox infection to others during post-exposure vaccination clinics.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Find out about the symptoms of COVID-19, what to do if you or your child has them and when to get medical help.
Explains how commissioners and health professionals can use data and analysis for decisions about neurology services and interventions.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.